This study revealed, for the first time, a correlation between the presence of metabolic syndrome (MetS) in DLBCL patients and several crucial factors, namely age, IPI score, use of rituximab, and levels of Ki-67 expression. This evidence concerns the gene MKI67 and diffuse large B-cell lymphoma.